Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Ibrutinib, Venetoclax Plus Obinutuzumab in Newly Diagnosed Mantle Cell Lymphoma Patients

Steven Le Gouill, MD PhD, Franck Morschhauser, MD, Kamal Bouabdallah, MD, Guillaume Cartron, Olivier Casasnovas, MD, Thomas Gastinne, MD, Patrice Chevallier, MD, Cédric Rossi, MD PhD, Emmanuelle Tchernonog, MD, Rory McCulloch, FRCPath, MRCP, MBBS, Charles Herbaux, MD, David Chiron, PhD, Mary Callanan, PhD, Simon Rule

Blood (2019) 134 (Supplement_1): 1530.

https://doi.org/10.1182/blood-2019-125681

Published: 2019

Journal Articles

Ibrutinib Plus Obinutuzumab and Venetoclax in Relapsed/Refractory Mantle Cells Lymphoma Patients, Results of the OASIS Phase I Clinical Trial

Steven Le Gouill, MD PhD, Franck Morschhauser, MD, Krimo Bouabdallah, MD, Guillaume Cartron, Rene-Olivier Casasnovas, MD, Noel-Jean Milpied, MD, Thomas Gastinne, MD, Andrew John Davies, PhD, Charles Herbaux, MD, David Chiron, PhD, Mary Callanan, PhD, Simon Rule, MD

Blood (2018) 132 (Supplement 1): 4158.

https://doi.org/10.1182/blood-2018-99-113777

Published: 2018

Journal Articles

Poor Prognosis Associated with Gains of CCND1 in Mantle Cell Lymphoma Treated By First Line Immuno-Chemotherapy — a Study By the Lysa Group

Blood (2018) 132 (Supplement 1): 4099.

https://doi.org/10.1182/blood-2018-99-113303

Published: 2018

Journal Articles

Correlations between p16 Protein Expression and Genomic Profile in Mantle Cell Lymphoma and Impact on Survival, a Lyma-Genomic Project Conducted on Behalf of the Lysa Group

Yannick LE Bris, MDPharmD, Danielle Canioni, MD, Barbara Burroni, MD, Anne Moreau, MD, Benoit Tessoulin, MD, Florence Magrangeas, PhD, Marie-Helene Delfau, MD, Catherine Thieblemont, MD, Lucie Oberic, MD, Krimo Bouabdallah, MD, Emmanuel Gyan, MD PhD, David Chiron, PhD, Catherine Pellat-deceunynck, PhD, Mary Callanan, PhD, Stephane Minvielle, PhD, Marie C Bene, PharmSci, PhD, Olivier Hermine, MD PhD, Steven Le Gouill, MD PhD

Blood (2018) 132 (Supplement 1): 2846.

https://doi.org/10.1182/blood-2018-99-113268

Published: 2018

Journal Articles

CSF1R and BTK Inhibitions As Novel Strategies to Disrupt the Dialogue between Mantle Cell Lymphoma and Macrophages

Antonin Papin, Benoit Tessoulin, MD, Céline Bellanger, Anne Moreau, MD, Yannick LE Bris, MDPharmD, Herve Maisonneuve, MD, Philippe Moreau, Cyrille Touzeau, MD PhD, Martine Amiot, PhD, Catherine Pellat-Deceunynck, PhD, Steven Le Gouill, MD PhD, David Chiron, PhD

Blood (2018) 132 (Supplement 1): 2855.

https://doi.org/10.1182/blood-2018-99-114504

Published: 2018

Journal Articles

Lymphoid-like Environment, Which Promotes Proliferation and Induces Resistance to BH3-Mimetics, Is Counteracted By Obinutuzumab in MCL: Biological Rationale for the Oasis Clinical Trial

David Chiron, PhD, Celine Bellanger, Antonin Papin, Benoit Tessoulin, MD, Christelle Dousset, Sophie Maiga, Anne Moreau, MD, Julie Esbelin, MD, Valerie Trichet, PhD, Selina Chen-Kiang, PhD, Philippe Moreau, Cyrille Touzeau, MD, Steven Le Gouill, MD PhD, Martine Amiot, Catherine Pellat-Deceunynck, PhD

Blood (2016) 128 (22): 1096.

https://doi.org/10.1182/blood.V128.22.1096.1096

Published: 2016

Journal Articles

High-Resolution Whole-Genome Copy Number Profiling Identifies High-Risk and Low-Risk Patients with Mantle Cell Lymphoma, a Result of the Lyma-Genomic Project Conducted on Behalf the Lysa Group

Yannick Le Bris, PharmD, Florence Magrangeas, Olivier Hermine, MD PhD, David Chiron, PhD, Danielle Canioni, Anne Moreau, MD, Marie C Bene, PharmSciD, PhD, Loic Campion, Stephane Minvielle, Steven Le Gouill, MD PhD

Blood (2016) 128 (22): 1745.

https://doi.org/10.1182/blood.V128.22.1745.1745

Published: 2016

Journal Articles

Sensitizing shRNA Screen for Molecular Targets in CDK4/CDK6-Based Combination Therapy in Multiple Myeloma

Xiangao Huang, PhD, Maurizio Di Liberto, PhD, David Chiron, PhD, Ruben Niesvizky, MD, Anna C. Schinzel, PhD, William C. Hahn, MD PhD, Selina Chen-Kiang, PhD

Blood (2014) 124 (21): 3440.

https://doi.org/10.1182/blood.V124.21.3440.3440

Published: 2014

Journal Articles

The Combination Of Palbociclib Plus Bortezomib Is Safe and Active In Patients With Previously Treated Mantle Cell Lymphoma: Final Results Of a Phase I Trial

Peter Martin, MD, Maurizio DiLiberto, PhD, Christopher E Mason, PhD, Scott A Ely, M.D., Jia Ruan, MD, PhD, Richard R. Furman, MD, David Chiron, PhD, Xiangao Huang, PhD, David C Madoff, M.D., Jonathan Navi, Jessica Lewis, PA-C, Alison Bender, PA-C, Amelyn Rodriguez, RN, June Greenberg, RN, Morton Coleman, MD, Selina Chen-Kiang, PhD, John P. Leonard, M.D.

Blood (2013) 122 (21): 4393.

https://doi.org/10.1182/blood.V122.21.4393.4393

Published: 2013

Journal Articles

Integrative Whole Transcriptome and Exome Sequencing Reveals Reprogramming Of Mantle Cell Lymphoma In Prolonged Early G1 Arrest For Clinical Response To Selective Inhibition Of CDK4 In Combination Therapy

David Chiron, PhD, Peter Martin, MD, Maurizio Di Liberto, Ph.D., Xiangao Huang, PhD, Priyanka Vijay, B.A, Pedro Blecua, PhD, Scott A Ely, MD, MPH, Olivier Elemento, PhD, Christopher E Mason, PhD, John P. Leonard, MD, Selina Chen-Kiang, PhD

Blood (2013) 122 (21): 80.

https://doi.org/10.1182/blood.V122.21.80.80

Published: 2013

Journal Articles

Induction of Early G1-Arrest by CDK4/CDK6 Inhibition Sensitizes Mantle Cell Lymphoma Cells to Selective PI3Kδ Inhibition by GS-1101 Through Enhancing the Magnitude and Duration of p-AKT Inhibition

David Chiron, PhD, Peter Martin, MD, Maurizio Di Liberto, Ph.D., Xiangao Huang, PhD, Scott A Ely, MD, MPH, Brian J. Lannutti, PhD, John P. Leonard, MD, Christopher E. Mason, PhD, Selina Chen-Kiang, PhD

Blood (2012) 120 (21): 791.

https://doi.org/10.1182/blood.V120.21.791.791

Published: 2012

Journal Articles

Mutation Burden in CDKN2C, CDK1 and E2F2 Is Associated with Differential Response to Targeting CDK4/CDK6 in Combination with Bortezomib in Mantle Cell Lymphoma,

Christopher E. Mason, PhD, Maurizio Di Liberto, Ph.D., Xiangao Huang, PhD, David Chiron, PhD, Jamieson Bretz, Ph.D., Ramsey Abdallah, B.S., Scott A Ely, M.D., Daniel M Knowles, MD, Peter Martin, MD, John P. Leonard, MD, Selina Chen-Kiang, PhD

Blood (2011) 118 (21): 3738.

https://doi.org/10.1182/blood.V118.21.3738.3738

Published: 2011

Journal Articles

Bim Is Required to Sensitize Mantle Cell Lymphoma Cells for Killing by Bortezomib, but Not Ara-C, by Selective Inhibition of CDK4/CDK6

Xiangao Huang, PhD, Maurizio Di Liberto, Ph.D., Jamieson Bretz, Ph.D., David Chiron, PhD, Peter Martin, MD, Morton Coleman, MD, Jia Ruan, MD, PhD, Mitchell R Smith, MD, PhD, Scott A Ely, M.D., Christopher E. Mason, PhD, Phoebe Joy Ho, MBBS, DPhil, John P. Leonard, MD, Selina Chen-Kiang, PhD

Blood (2011) 118 (21): 1655.

https://doi.org/10.1182/blood.V118.21.1655.1655

Published: 2011

Journal Articles

TP53 Positively Regulates Cell Death through TRAILR2 (DR5) but Negatively through TRAILR1 (DR4) In Myeloma Cells

Sylvanie Surget, PhD, in, training, Patricia Gomez-Bougie, David Chiron, PhD, in, training, Robin Humphreys, PhD, Philippe Moreau, Steven Le Gouill, Jean-Luc Harousseau, Regis Bataille, MD, PhD, Martine Amiot, Catherine Pellat-Deceunynck, PhD

Blood (2010) 116 (21): 136.

https://doi.org/10.1182/blood.V116.21.136.136

Published: 2010

Journal Articles

Myeloma Cell Self-Renewal Depends on JAG2 Expression and Is Mediated by IGF1 or SCF Loop

David Chiron, PhD, in, training, Sophie Maiga, Géraldine Descamps, Severine Marionneau, Thilbaud Ouiller, Jerome Moreaux, Bernard Klein, PhD, MD, Philippe Moreau, Jean-Luc Harousseau, Regis Bataille, MD, PhD, Martine Amiot, Catherine Pellat-Deceunynck, PhD

Blood (2010) 116 (21): 127.

https://doi.org/10.1182/blood.V116.21.127.127

Published: 2010

NARROW

Ibrutinib, Venetoclax Plus Obinutuzumab in Newly Diagnosed Mantle Cell Lymphoma Patients

Ibrutinib Plus Obinutuzumab and Venetoclax in Relapsed/Refractory Mantle Cells Lymphoma Patients, Results of the OASIS Phase I Clinical Trial

Poor Prognosis Associated with Gains of CCND1 in Mantle Cell Lymphoma Treated By First Line Immuno-Chemotherapy — a Study By the Lysa Group

Correlations between p16 Protein Expression and Genomic Profile in Mantle Cell Lymphoma and Impact on Survival, a Lyma-Genomic Project Conducted on Behalf of the Lysa Group

CSF1R and BTK Inhibitions As Novel Strategies to Disrupt the Dialogue between Mantle Cell Lymphoma and Macrophages

Lymphoid-like Environment, Which Promotes Proliferation and Induces Resistance to BH3-Mimetics, Is Counteracted By Obinutuzumab in MCL: Biological Rationale for the Oasis Clinical Trial

High-Resolution Whole-Genome Copy Number Profiling Identifies High-Risk and Low-Risk Patients with Mantle Cell Lymphoma, a Result of the Lyma-Genomic Project Conducted on Behalf the Lysa Group

Sensitizing shRNA Screen for Molecular Targets in CDK4/CDK6-Based Combination Therapy in Multiple Myeloma

The Combination Of Palbociclib Plus Bortezomib Is Safe and Active In Patients With Previously Treated Mantle Cell Lymphoma: Final Results Of a Phase I Trial

Integrative Whole Transcriptome and Exome Sequencing Reveals Reprogramming Of Mantle Cell Lymphoma In Prolonged Early G1 Arrest For Clinical Response To Selective Inhibition Of CDK4 In Combination Therapy

Induction of Early G1-Arrest by CDK4/CDK6 Inhibition Sensitizes Mantle Cell Lymphoma Cells to Selective PI3Kδ Inhibition by GS-1101 Through Enhancing the Magnitude and Duration of p-AKT Inhibition

Mutation Burden in CDKN2C, CDK1 and E2F2 Is Associated with Differential Response to Targeting CDK4/CDK6 in Combination with Bortezomib in Mantle Cell Lymphoma,

Bim Is Required to Sensitize Mantle Cell Lymphoma Cells for Killing by Bortezomib, but Not Ara-C, by Selective Inhibition of CDK4/CDK6

TP53 Positively Regulates Cell Death through TRAILR2 (DR5) but Negatively through TRAILR1 (DR4) In Myeloma Cells

Myeloma Cell Self-Renewal Depends on JAG2 Expression and Is Mediated by IGF1 or SCF Loop

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only